What regulators are investigating
The EMA opened a formal review in 2023 after multiple reports of suicidal thoughts and self-injury in patients taking semaglutide and liraglutide. The FDA also added new language to GLP-1 labels and continues to monitor the signal.
When mental-health claims may qualify
Documented new-onset suicidal ideation, suicide attempt, or psychiatric hospitalization with no prior history, beginning during or shortly after GLP-1 therapy, are the strongest factual patterns. A licensed attorney will assess your specific case.